GlaxoSmithKline: raises 2019 guidance after 'good progress'
(CercleFinance.com) - GlaxoSmithKline raised it full-year EPS guidance after making "good progress" in the third quarter, the British drugmaker said on Wednesday.
GSK now expects 2019 adjusted EPS to fairly flat at constant exchange rates (CER), from a previous guidance of an expected decline in the range of -3% to -5%, as provided in July.
Third-quarter EPS fell by 1% on sales that rose by 11% to 9.4 billion pounds.
Sales of vaccines rose by 20% by 15% to 2.3 billion pounds, GSK said, while consumer healthcare sales jumped by 25% to 2.5 billion pounds, primarily reflecting the acquired Pfizer legacy brands.
GSK said that it continued to strengthen its pipeline over the quarter and has advanced assets in respiratory, HIV and, notably, oncology, where the drugmaker is on track to file three innovative medicines by the end of the year following "positive" pivotal trial data.
The shares were up 1.8% in London after this report.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
GSK now expects 2019 adjusted EPS to fairly flat at constant exchange rates (CER), from a previous guidance of an expected decline in the range of -3% to -5%, as provided in July.
Third-quarter EPS fell by 1% on sales that rose by 11% to 9.4 billion pounds.
Sales of vaccines rose by 20% by 15% to 2.3 billion pounds, GSK said, while consumer healthcare sales jumped by 25% to 2.5 billion pounds, primarily reflecting the acquired Pfizer legacy brands.
GSK said that it continued to strengthen its pipeline over the quarter and has advanced assets in respiratory, HIV and, notably, oncology, where the drugmaker is on track to file three innovative medicines by the end of the year following "positive" pivotal trial data.
The shares were up 1.8% in London after this report.
Copyright (c) 2019 CercleFinance.com. All rights reserved.